Loading…

THU-464 aMAP score predicts progression-free survival in patients receiving atezolizumab plus bevacizumab for hepatocellular carcinoma

Saved in:

Bibliographic Details
Published in:	Journal of hepatology 2024-06, Vol.80, p.S443-S443
Main Authors:	Vithayathil, Mathew, D'Alessio, Antonio, Fulgenzi, Claudia, Celsa, Ciro, Manfredi, Giulia, Nishida, Naoshi, Schoenlein, Martin, von Felden, Johann, Schulze, Kornelius, Wege, Henning, Saeed, Anwaar, Wietharn, Brooke, Hildebrand, Hannah, Wu, Linda, Ang, Celina, Marron, Thomas U., Weinmann, Arndt, Galle, Peter R., Bettinger, Dominik, Lin, Chun-yen, Vogel, Arndt, Scheiner, Bernhard, Lee, Pei-Chang, Huang, Yi-Hsiang, Amara, Suneetha, Muzaffar, Mahvish, Naqash, Abdul Rafeh, Zanuso, Valentina, Pressiani, Tiziana, Cabibbo, Giuseppe, Dalbeni, Andrea, Pinter, Matthias, Singal, Amit, Chon, Hong Jae, Cortellini, Alessio, Kudo, Masatoshi, Rimassa, Lorenza, Pinato, David J., Sharma, Rohini
Format:	Article
Language:	English
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!